{"entity":{"id":"charm-therapeutics","kind":"company","name":"CHARM Therapeutics","aka":["Charm Therapeutics","CHARM Therapeutics Ltd"],"tldr":"CHARM Therapeutics is a London and Cambridge company using an AI protein-modelling tool to design medicines. Its first drug, CHM-029, is a menin inhibitor for acute myeloid leukaemia, built to keep working when the leukaemia becomes resistant to the first menin inhibitors.","summary":"CHARM Therapeutics Ltd has offices at Pancras Square in London and on the Babraham Research Campus near Cambridge. It designs small molecules with DragonFold, its protein-ligand co-folding platform, and its lead programme CHM-029 is a menin inhibitor designed to mimic the binding of KMT2A to menin and to retain potency against the menin resistance mutations described with first-generation inhibitors. The company names Laksh Aithani and David Baker as co-founders. In September 2025 it closed an oversubscribed USD 80 million Series B co-led by New Enterprise Associates and SR One, with OrbiMed, F-Prime, Khosla Ventures and NVIDIA participating, and it states it has raised more than USD 150 million in total. Its first registered cancer trial, NCT07751991, a phase 1/2 first-in-human study of CHM-029 in relapsed or refractory acute myeloid leukaemia with NPM1 mutations or KMT2A or NUP98 rearrangements at sites in the United States and United Kingdom, was posted on ClinicalTrials.gov in August 2026; the company announced in October 2026 that the first cohort had been dosed and fully enrolled.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://charmtx.com/"},{"label":"Series B release, September 2025","url":"https://charmtx.com/charm-therapeutics-raises-80-million-in-series-b-financing-to-advance-development-of-best-in-class-menin-inhibitor-for-aml/"},{"label":"First patient dosed with CHM-029, October 2026","url":"https://charmtx.com/charm-therapeutics-announces-first-patient-dosed-and-first-cohort-fully-enrolled-in-its-phase-i-ii-clinical-trial-of-chm-029-for-aml/"},{"label":"ClinicalTrials.gov: phase 1/2 trial of CHM-029 in AML (NCT07751991)","url":"https://clinicaltrials.gov/study/NCT07751991"}],"tags":[],"related":[],"cancers":["aml","aml-npm1-kmt2a"],"sections":["targeted-therapy","ai-computation"],"technologies":["menin-inhibitors","ai-drug-design"],"targets":["menin","kmt2a","npm1","nup98"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website. Financing, platform and trial facts read on charmtx.com and the ClinicalTrials.gov record for NCT07751991 on 29 October 2026. The company's resistance and safety claims for CHM-029 are preclinical and its own."],"hq":"London","country":"GB","companyType":"biotech","website":"https://charmtx.com/","stage":"growth","investors":["orbimed","f-prime-capital","khosla-ventures","sr-one"],"funding":[{"round":"Series B","year":2025,"amountUsd":80000000,"source":"https://charmtx.com/charm-therapeutics-raises-80-million-in-series-b-financing-to-advance-development-of-best-in-class-menin-inhibitor-for-aml/","note":"Co-led by New Enterprise Associates and SR One, with OrbiMed, F-Prime, Khosla Ventures and NVIDIA"}]},"route":"/companies/charm-therapeutics/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"menin-inhibitors","kind":"technology","name":"Menin inhibitors","route":"/technologies/menin-inhibitors/"}],"target":[{"id":"kmt2a","kind":"target","name":"KMT2A (MLL) rearrangement","route":"/targets/kmt2a/"},{"id":"menin","kind":"target","name":"Menin","route":"/targets/menin/"},{"id":"npm1","kind":"target","name":"NPM1 mutation","route":"/targets/npm1/"},{"id":"nup98","kind":"target","name":"NUP98","route":"/targets/nup98/"}],"company":[{"id":"f-prime-capital","kind":"company","name":"F-Prime Capital","route":"/companies/f-prime-capital/"},{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/"},{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"},{"id":"sr-one","kind":"company","name":"SR One","route":"/companies/sr-one/"}]}}